Cited by 72

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism

Kristensen, Kristian K., Leth-Espensen, Katrine Zinck, Mertens, Haydyn D. T., Birrane, Gabriel, Meiyappan, Muthuraman, Olivecrona, Gunilla, Jørgensen, Thomas J. D., Young, Stephen G., Ploug, Michael·2020·Proceedings of the National Academy of Sciences

Abstract

The binding of lipoprotein lipase (LPL) to GPIHBP1 focuses the intravascular hydrolysis of triglyceride-rich lipoproteins on the surface of capillary endothelial cells. This process provides essential lipid nutrients for vital tissues (e.g., heart, skeletal muscle, and adipose tissue). Deficiencies in either LPL or GPIHBP1 impair triglyceride hydrolysis, resulting in severe hypertriglyceridemia. The activity of LPL in tissues is regulated by angiopoietin-like proteins 3, 4, and 8 (ANGPTL). Dogma has held that these ANGPTLs inactivate LPL by converting LPL homodimers into monomers, rendering them highly susceptible to spontaneous unfolding and loss of enzymatic activity. Here, we show that binding of an LPL-specific monoclonal antibody (5D2) to the tryptophan-rich lipid-binding loop in the carboxyl terminus of LPL prevents homodimer formation and forces LPL into a monomeric state. Of note, 5D2-bound LPL monomers are as stable as LPL homodimers (i.e., they are not more prone to unfolding), but they remain highly susceptible to ANGPTL4-catalyzed unfolding and inactivation. Binding of GPIHBP1 to LPL alone or to 5D2-bound LPL counteracts ANGPTL4-mediated unfolding of LPL. In conclusion, ANGPTL4-mediated inactivation of LPL, accomplished by catalyzing the unfolding of LPL, does not require the conversion of LPL homodimers into monomers. Thus, our findings necessitate changes to long-standing dogma on mechanisms for LPL inactivation by ANGPTL proteins. At the same time, our findings align well with insights into LPL function from the recent crystal structure of the LPL•GPIHBP1 complex.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.1920202117

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ANGPTL4 can act on monomeric LPL and increases the inherent instability of LPL resulting in unfolding of LPL's catalytic domain.

    “Indeed, a recent series of studies from the laboratory of Michael Ploug have shown that ANGPTL4 can act on monomeric LPL, and that ANGPTL4 increases the inherent instability of LPL resulting in the unfolding of LPL’s catalytic domain (52, 97, 98).”
  • Several studies have indicated that ANGPTL4 catalytically inactivates LPL.

    “Several studies have indicated that ANGPTL4 catalytically inactivates LPL (49, 51, 52, 97, 98).”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 55

  1. S. G. Young, R. Zechner, Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev. 27, 459–484 (2013). · DOI
  2. C. N. Goulbourne ., The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab. 19, 849–860 (2014). · DOI · Paper page
  3. B. S. Davies ., GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 12, 42–52 (2010). · DOI · Paper page
  4. S. Mysling ., The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding. eLife 5, e20958 (2016). · DOI · Paper page
  5. W. K. Sonnenburg ., GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. J. Lipid Res. 50, 2421–2429 (2009). · DOI · Paper page
  6. O. Kovrov, K. K. Kristensen, E. Larsson, M. Ploug, G. Olivecrona, On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. J. Lipid Res. 60, 783–793 (2019). · DOI · Paper page
  7. A. P. Beigneux ., Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia. N. Engl. J. Med. 376, 1647–1658 (2017). · DOI
  8. W. Plengpanich ., Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain. J. Biol. Chem. 289, 19491–19499 (2014). · DOI
  9. A. P. Beigneux ., GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding. Circ. Res. 116, 624–632 (2015). · DOI
  10. X. Hu ., GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia. J. Clin. Lipidol. 11, 964–971 (2017). · DOI
  11. M. J. Ariza ., Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis. J. Clin. Lipidol. 10, 92–100.e1 (2016). · DOI
  12. L. G. Fong ., GPIHBP1 and plasma triglyceride metabolism. Trends Endocrinol. Metab. 27, 455–469 (2016). · DOI
  13. A. Helgadottir ., Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat. Genet. 48, 634–639 (2016). · DOI
  14. S. Romeo ., Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119, 70–79 (2009).
  15. S. Mysling ., The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain. eLife 5, e12095 (2016). · DOI
  16. H. Wong ., Lipoprotein lipase domain function. J. Biol. Chem. 269, 10319–10323 (1994). · DOI
  17. H. Wong ., A molecular biology-based approach to resolve the subunit orientation of lipoprotein lipase. Proc. Natl. Acad. Sci. U.S.A. 94, 5594–5598 (1997). · DOI
  18. H. van Tilbeurgh, A. Roussel, J. M. Lalouel, C. Cambillau, Lipoprotein lipase. Molecular model based on the pancreatic lipase x-ray structure: Consequences for heparin binding and catalysis. J. Biol. Chem. 269, 4626–4633 (1994). · DOI
  19. Y. Kobayashi, T. Nakajima, I. Inoue, Molecular modeling of the dimeric structure of human lipoprotein lipase and functional studies of the carboxyl-terminal domain. Eur. J. Biochem. 269, 4701–4710 (2002). · DOI
  20. C. K. Hayne ., We FRET so you don’t have to: New models of the lipoprotein lipase dimer. Biochemistry 57, 241–254 (2018). · DOI
  21. A. Lookene, L. Zhang, M. Hultin, G. Olivecrona, Rapid subunit exchange in dimeric lipoprotein lipase and properties of the inactive monomer. J. Biol. Chem. 279, 49964–49972 (2004). · DOI
  22. J. C. Osborne,Jr, G. Bengtsson-Olivecrona, N. S. Lee, T. Olivecrona, Studies on inactivation of lipoprotein lipase: Role of the dimer to monomer dissociation. Biochemistry 24, 5606–5611 (1985). · DOI
  23. J. Peterson, W. Y. Fujimoto, J. D. Brunzell, Human lipoprotein lipase: Relationship of activity, heparin affinity, and conformation as studied with monoclonal antibodies. J. Lipid Res. 33, 1165–1170 (1992). · DOI
  24. V. Sukonina, A. Lookene, T. Olivecrona, G. Olivecrona, Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. U.S.A. 103, 17450–17455 (2006). · DOI · Paper page
  25. L. Shan ., The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J. Biol. Chem. 284, 1419–1424 (2009). · DOI · Paper page
  26. G. Birrane ., Structure of the lipoprotein lipase-GPIHBP1 complex that mediates plasma triglyceride hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 116, 1723–1732 (2019). · DOI
  27. R. Arora ., Structure of lipoprotein lipase in complex with GPIHBP1. Proc. Natl. Acad. Sci. U.S.A. 116, 10360–10365 (2019). · DOI
  28. C. F. Cheng, A. Bensadoun, T. Bersot, J. S. Hsu, K. H. Melford, Purification and characterization of human lipoprotein lipase and hepatic triglyceride lipase. Reactivity with monoclonal antibodies to hepatic triglyceride lipase. J. Biol. Chem. 260, 10720–10727 (1985). · DOI
  29. G. Bengtsson-Olivecrona, T. Olivecrona, Phospholipase activity of milk lipoprotein lipase. Methods Enzymol. 197, 345–356 (1991). · DOI
  30. A. P. Beigneux ., Lipoprotein lipase is active as a monomer. Proc. Natl. Acad. Sci. U.S.A. 116, 6319–6328 (2019). · DOI · Paper page
  31. S. G. Young ., GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metab. 30, 51–65 (2019). · DOI
  32. S. F. Chang, B. Reich, J. D. Brunzell, H. Will, Detailed characterization of the binding site of the lipoprotein lipase-specific monoclonal antibody 5D2. J. Lipid Res. 39, 2350–2359 (1998). · DOI
  33. A. Lookene, N. B. Groot, J. J. Kastelein, G. Olivecrona, T. Bruin, Mutation of tryptophan residues in lipoprotein lipase. Effects on stability, immunoreactivity, and catalytic properties. J. Biol. Chem. 272, 766–772 (1997). · DOI
  34. S. P. Babirak, P. H. Iverius, W. Y. Fujimoto, J. D. Brunzell, Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis 9, 326–334 (1989). · DOI
  35. M. S. Liu, Y. Ma, M. R. Hayden, J. D. Brunzell, Mapping of the epitope on lipoprotein lipase recognized by a monoclonal antibody (5D2) which inhibits lipase activity. Biochim. Biophys. Acta 1128, 113–115 (1992). · DOI
  36. X. Hu ., Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL. J. Lipid Res. 58, 208–215 (2017). · DOI
  37. K. Miyashita ., An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum. J. Clin. Lipidol. 12, 203–210.e1 (2018). · DOI
  38. K. K. Kristensen ., A disordered acidic domain in GPIHBP1 harboring a sulfated tyrosine regulates lipoprotein lipase. Proc. Natl. Acad. Sci. U.S.A. 115, E6020–E6029 (2018). · DOI
  39. M. B. Trelle ., An asymmetric runaway domain swap antithrombin dimer as a key intermediate for polymerization revealed by hydrogen/deuterium-exchange mass spectrometry. Anal. Chem. 89, 616–624 (2017). · DOI
  40. Z. Ahmad ., Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation 140, 470–486 (2019). · DOI
  41. W. J. Geldenhuys, L. Lin, A. S. Darvesh, P. Sadana, Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. Drug Discov. Today 22, 352–365 (2017). · DOI
  42. S. Kersten, New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk. Curr. Opin. Lipidol. 30, 205–211 (2019). · DOI
  43. M. J. Lafferty, K. C. Bradford, D. A. Erie, S. B. Neher, Angiopoietin-like protein 4 inhibition of lipoprotein lipase: Evidence for reversible complex formation. J. Biol. Chem. 288, 28524–28534 (2013). · DOI · Paper page
  44. A. R. Gutgsell, S. V. Ghodge, A. A. Bowers, S. B. Neher, Mapping the sites of the lipoprotein lipase (LPL)-angiopoietin-like protein 4 (ANGPTL4) interaction provides mechanistic insight into LPL inhibition. J. Biol. Chem. 294, 2678–2689 (2019). · DOI
  45. G. Bengtsson, T. Olivecrona, Apolipoprotein CII enhances hydrolysis of monoglycerides by lipoprotein lipase, but the effect is abolished by fatty acids. FEBS Lett. 106, 345–348 (1979). · DOI
  46. M. H. Yau ., A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J. Biol. Chem. 284, 11942–11952 (2009). · DOI · Paper page
  47. D. M. Ferraro, N. Lazo, A. D. Robertson, EX1 hydrogen exchange and protein folding. Biochemistry 43, 587–594 (2004). · DOI
  48. 10.1074/jbc.RA119.011079 · DOI
  49. M. Péterfy, Lipase maturation factor 1: A lipase chaperone involved in lipid metabolism. Biochim. Biophys. Acta 1821, 790–794 (2012). · DOI
  50. L. Zhang, A. Lookene, G. Wu, G. Olivecrona, Calcium triggers folding of lipoprotein lipase into active dimers. J. Biol. Chem. 280, 42580–42591 (2005). · DOI
  51. C. M. Koerner, B. S. Roberts, S. B. Neher, Endoplasmic reticulum quality control in lipoprotein metabolism. Mol. Cell. Endocrinol. 498, 110547 (2019). · DOI
  52. E. L. Sundberg, Y. Deng, C. G. Burd, Syndecan-1 mediates sorting of soluble lipoprotein lipase with sphingomyelin-rich membrane in the Golgi apparatus. Dev. Cell 51, 387–398.e4 (2019). · DOI
  53. T. Robal, M. Larsson, M. Martin, G. Olivecrona, A. Lookene, Fatty acids bind tightly to the N-terminal domain of angiopoietin-like protein 4 and modulate its interaction with lipoprotein lipase. J. Biol. Chem. 287, 29739–29752 (2012). · DOI · Paper page
  54. J. M. Leth, H. D. T. Mertens, K. Z. Leth-Espensen, T. J. D. Jørgensen, M. Ploug, Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond? J. Biol. Chem. 294, 7403–7418 (2019). · DOI
  55. M. Guttman, D. D. Weis, J. R. Engen, K. K. Lee, Analysis of overlapped and noisy hydrogen/deuterium exchange mass spectra. J. Am. Soc. Mass Spectrom. 24, 1906–1912 (2013). · DOI

Cited by

Sorted by citations

Metadata

Authors
Kristensen, K. K., Leth-Espensen, K. Z., Mertens, H. D. T., Birrane, G., Meiyappan, M., Olivecrona, G., Jørgensen, T. J. D., Young, S. G., & Ploug, M.
Affiliations
  • Finsen Laboratory, Rigshospitalet, DK–2200 Copenhagen N, Denmark;
  • BIOSAXS Group, European Molecular Biology Laboratory Hamburg, D-22607 Hamburg, Germany;
  • Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215;
  • Discovery Therapeutics, Takeda Pharmaceutical Company Ltd., Cambridge, MA 02142;
  • Department of Medical Biosciences, Umeå University, 901 87 Umeå, Sweden;
  • Department of Biochemistry and Molecular Biology, University of Southern Denmark, DK–5320 Odense M, Denmark;
  • Department of Medicine, University of California, Los Angeles, CA 90095;
Venue
Proceedings of the National Academy of Sciences
Published
2020-02-07
Volume
117
Issue
8
Pages
4337-4346
ISSN
  • 0027-8424
  • 1091-6490
Cited by
72
References
6
Language
en
Funders
  • HHS | National Institutes of Health (HL090553, HL087228, HL125335)
  • Fondation Leducq (12CVD04)
  • Lundbeckfonden (R230-2016-2930)
  • Novo Nordisk (NNF17OC0026868, NNF18OC0033864)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review